Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

HSCT: How Does It Work?

In: The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT [Internet]. Cham (CH): Springer; 2018. Chapter 2.
.
Affiliations
Free Books & Documents
Review

HSCT: How Does It Work?

Letizia Galgano et al.
Free Books & Documents

Excerpt

The HSCT (haematopoietic stem cell transplant) is a particular treatment for many haematological and non-haematological diseases. Broadly, there are three different categories of transplantation, autologous, allogeneic and syngeneic, which can be applied to most disease scenarios. Haematopoietic stem cells can be derived from the bone marrow, peripheral blood and umbilical cord blood. HSCT treatment can be divided into separate phases that start with the harvest of the stem cells and passing through the conditioning, aplasia and engraftment until the recovery of the haematopoietic functions. HSCT is indicated in many diseases, and these indications depend on numerous factors such as the disease type, stage and response to previous treatment. Among non-malignant diseases, aplastic anaemia, sickle cell disease and, more recently, autoimmune diseases can also be effectively treated with HSCT. One third of the transplants in children are performed for rare indications such as severe combined immunodeficiencies. Allogeneic HSCT can also cure a number of non-malignant diseases in children, such as Wiskott-Aldrich syndrome and chronic granulomatous disease (CGD). This chapter will include transplant in primary immunodeficiency in children as well as inherited bone marrow failure and inborn errors of metabolism.

PubMed Disclaimer

References

    1. Apperley J, Carreras E, Gluckman E, Masszi T. editors. ESH-EBMT handbook. 2012, [Online] pp. 111, 309, 311.
    1. Aversa F. T-cell depletion: from positive selection to negative depletion in adult patients. Bone Marrow Transplant. 2015;50:S11–3. - PubMed
    1. Bashey A, Solomon SR. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant. 2014;49:999–1008. - PubMed
    1. Champlin RE. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95:3702–9. - PubMed
    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26. - PubMed
References for Indications for Transplant in Non-malignant Diseases in Children
    1. Barbaro P, Vedi A. Survival after hematopoietic stem cell transplant in patients with dyskeratosis congenita: systematic review of the literature. Biol Blood Marrow Transplant. 2016;22:1152–8. - PubMed
    1. Boelens JJ, Wynn RF, Bierings M. HSCT for inborn errors of metabolism. In: Carreras E, Gluckman E, Gratwohl A, Masszi T, Apperley J, editors. Haematopoietic stem cell transplantation, 5th. s.l. France, Paris: ESH EBMT; 2008. p. 544–53.
    1. Booth C, Silva J, Veys P. Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future. Expert Rev Clin Immunol. 2016;12:713–23. https://doi.org/10.1586/1744666X.2016.1150177. - DOI - PubMed
    1. Dvorak CC, Hassan A, Slatter MA, Hönig M, Lankester AC, Buckley RH, Pulsipher MA, Davis JH, Güngör T, Gabriel M, Bleesing JH, Bunin N, Sedlacek P, Connelly JA, Crawford DF, Notarangelo LD, Pai SY, Hassid J, Veys P, Gennery AR, Cowan MJ. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol. 2014;134:935–43. - PMC - PubMed
    1. EBMT & ESID- European Society for Immunodeficiencies have published in 2011 guidelines for stem cell transplantation for primary immunodeficiencies. [Online].

LinkOut - more resources